TG Therapeutics Inc. reported its fourth quarter and full-year 2024 financial results, with U.S. net revenue for BRIUMVI reaching $103.6 million in Q4 and $310 million for the full year. The company has set a target guidance of approximately $540 million in total global revenue for 2025. For the fourth quarter, product revenue, net, was approximately $107.3 million, a significant increase from $43.1 million in the same period of the previous year. Full-year product revenue, net, was $313.7 million, compared to $92.0 million in 2023. The company also reported a net income of $23.3 million for the quarter, with GAAP EPS of $0.15, meeting expectations. Sales for the quarter reached $108 million, beating the $100 million estimate. BRIUMVI's strong adoption drove a 250% year-over-year revenue growth. TG Therapeutics anticipates over $200 million in profits for 2025, based on total expenses of $300 million and a cash reserve of $313 million, achieved within just two years from launch. Ocular Therapeutix Inc. announced its financial results for the fourth quarter and full year 2024, reporting net revenue of $17.1 million for Q4 and $63.7 million for the full year. The company's cash balance stands at $392 million, which is expected to fund operations into 2028. Ocular Therapeutix does not plan to raise additional capital this year. The FDA has approved an amendment to the SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76. This change has shifted the Week 36 primary endpoint data expectation to the first quarter of 2026. The inclusion of re-dosing in the SOL-1 trial, coupled with high retention rates, has allowed for a reduction in the SOL-R trial size from 825 to 555 subjects, potentially accelerating registration timelines. The company reported a GAAP EPS of $(0.29) and sales of $17.08 million for the quarter, missing estimates.